Anti-miR and gene therapy to heal the diseased heart

Cardiac remodelling leads to heart failure (HF) which represents a growing disease problem worldwide. Patients with HF have a high frequency of hospitalization and available pharmacological therapies are not sufficient to significantly reduce the high mortality. As standard care, physicians use potent blockers of e.g., single receptors in cardiac tissue thus impairing a single signalling cascade counteracting maladaptive cardiac deterioration. The identification of novel disease targets and the establishment of higher potency medication is thus an important aim in cardiovascular drug development. This strategy is supported by novel technologies sequencing whole genomes and highlighting the great majority of non-coding areas.